跳至主要内容
临床试验/NCT00909142
NCT00909142已完成不适用

Bonefos and the Consumption of Analgesics. Influence of Clodronate on Analgesics Consumption Among Patients With Bone Metastasis

Bayer0 个研究点目标入组 149 人开始时间: 2007年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
149
主要终点
Analgesics consumption after 12 months of treatment with Bonefos in patients with bone metastases and breast or prostate cancer or multiple myeloma

研究概览

简要总结

The effect of Bonefos on consumption of analgesics (drugs used for pain treatment) in patients with proven bone metastases.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Breast cancer or prostate cancer or multiple myeloma.
  • Bone metastasis.
  • Ability to use analgesics and clodronate 1600 mg/day.

排除标准

  • Hypersensitivity to bisphosphonates.
  • Clodronate in previous therapy.
  • Concomitant use of other bisphosphonates.
  • Serious renal insufficiency.

研究组 & 干预措施

Group1

干预措施: Bonefos (Clodronate, BAY94-8393) (Drug)

结局指标

主要结局

Analgesics consumption after 12 months of treatment with Bonefos in patients with bone metastases and breast or prostate cancer or multiple myeloma

时间窗: 12 months

次要结局

  • Decrease in pain measured by VAS (Visual Analogue Scale)(12 months)

研究者

发起方
Bayer
申办方类型
Industry

相似试验